Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Global Cord Blood ( (CORBF) ) has shared an announcement.
On June 2, 2025, the Joint Provisional Liquidators (JPLs) of Global Cord Blood Corporation submitted their twelfth report to the Grand Court of the Cayman Islands, continuing the process initiated on September 22, 2022, when the court appointed them under the Companies Act. The JPLs also communicated with shareholders regarding a summons filed on May 28, 2025, seeking court approval for their remuneration and disbursements from October 2023 to September 2024. They are requesting to dispense with the requirement for an Extraordinary General Meeting due to unresolved issues that previously led to a lack of quorum, aiming to streamline the process and reduce costs.
More about Global Cord Blood
Global Cord Blood Corporation operates in the healthcare industry, focusing on the collection, processing, and storage of umbilical cord blood stem cells for future medical use. The company primarily serves families looking to preserve stem cells for potential future therapeutic applications.
Average Trading Volume: 269,829
Technical Sentiment Signal: Sell
Current Market Cap: $133.9M
See more insights into CORBF stock on TipRanks’ Stock Analysis page.